{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:37:13Z","timestamp":1792064233550,"version":"4.4.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T00:00:00Z","timestamp":1354838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0051526","type":"journal-article","created":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T23:09:42Z","timestamp":1354921782000},"page":"e51526","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis"],"prefix":"10.1371","volume":"7","author":[{"given":"Hao","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Qiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,12,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"DM Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6602510","article-title":"State-of-the-art management of locally advanced head and neck cancer","volume":"92","author":"TY Seiwert","year":"2005","journal-title":"Br J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"DJ Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2004.08.021","article-title":"Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma","volume":"22","author":"F Denis","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B, <etal>et al<\/etal>.. (2006) Long-term results of Intergroup RTOG 91\u201311: A phase III trial to preserve the larynx\u2013Induction cisplatin\/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy.","DOI":"10.1200\/jco.2006.24.18_suppl.5517"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/jnci\/88.13.890","article-title":"Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group","volume":"88","author":"JL Lefebvre","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/86.4.265","article-title":"Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo","volume":"86","author":"A Paccagnella","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.1997.15.5.2050","article-title":"Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?","volume":"15","author":"PM Harari","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer","volume":"355","author":"JP Pignon","year":"2000","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/annonc\/mdh308","article-title":"Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience","volume":"15","author":"B Brockstein","year":"2004","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CCO.0b013e328329abe5","article-title":"Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects","volume":"21","author":"SR Chandana","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00405-003-0725-5","article-title":"Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma","volume":"262","author":"J Kutter","year":"2005","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Y Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"MR Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"JB Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1200\/JCO.2004.00.1990","article-title":"Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer","volume":"23","author":"R Hitt","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Giron CG, <etal>et al<\/etal>.. (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin\/5-FU or docetaxel\/cisplatin\/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol ASCO(suppl 15): abstr 6009.","DOI":"10.1200\/jco.2009.27.15_suppl.6009"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0165-6147(92)90048-B","article-title":"Mechanism of action of taxol","volume":"13","author":"SB Horwitz","year":"1992","journal-title":"Trends Pharmacol Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","article-title":"Taxol: a novel investigational antimicrotubule agent","volume":"82","author":"EK Rowinsky","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.5-3-199","article-title":"Role of taxoids in head and neck cancer","volume":"5","author":"D Schrijvers","year":"2000","journal-title":"Oncologist"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00001813-200404000-00004","article-title":"Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck","volume":"15","author":"JP Pignon","year":"2004","journal-title":"Anticancer Drugs"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/hed.21096","article-title":"Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck","volume":"31","author":"A Parthan","year":"2009","journal-title":"Head Neck"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial","volume":"12","author":"JH Lorch","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/0169-5002(95)00432-Z","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer","volume":"12","author":"PA Francis","year":"1995","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Yano R, Konno A, Watanabe K, Tsukamoto H, Kayano Y, <etal>et al<\/etal>.. (2011) Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol.","DOI":"10.1007\/s10147-011-0349-5"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0051526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T15:24:05Z","timestamp":1643815445000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0051526"}},"subtitle":[],"editor":[{"given":"Jose Luis","family":"Perez-Gracia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,7]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0051526","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969302.793470084","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,7]]}}}